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ABSTRACT
This study investigated the long-term outcome of
patients with tuberculosis (TB) as a complication
of tumour necrosis factor (TNF)-a blocker ther-
apy. All TB cases (n = 21) complicating TNF-a
blocker therapy from French university hospitals
were collated between January 2000 and Septem-
ber 2002. Outcome was assessed via a postal
questionnaire during September 2005. The mor-
tality rate after 4 years was 4.8%, and one patient
had relapsed and six (29%) patients had recom-
menced TNF-a antagonist treatment, after appro-
priate anti-TB therapy, without reactivation.
These data support the concept that TNF-a
antagonists can be restarted in TB patients pro-
vided that adequate anti-TB treatment has been
completed.
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Tumour necrosis factor (TNF)-a induces intracel-
lular death of Mycobacterium tuberculosis, macro-
phage apoptosis and granuloma formation [1–3].
Keane et al. [4] were the first to describe an
increased incidence of tuberculosis (TB) in
patients with rheumatoid arthritis treated with
TNF-a blockers. The relative risk of developing
TB while receiving this therapy in this patient
group has been estimated in the USA and Europe
at ‡4 [4–7]. In France, a national multidisciplinary
group (Recherche Axe´e sur la Tole´rance des
Biothe´rapies; RATIO) was formed to further
improve the knowledge, prevention and care of
opportunistic infections associated with TNF-a
antagonists. The present study describes the long-
term outcome of 21 patients in France who
developed TB while receiving TNF-a blockers.
Data concerning all cases of TB in patients
treated with TNF-a blockers between 1 January
2000 (the time at which TNF-a antagonists were
first used in France) and 30 September 2002 were
collected from the gastroenterology, rheumatol-
ogy, infectious diseases and internal medicine
units of all French university hospitals. On-site
visits took place between 15 October 2002 and 22
January 2003. Postal questionnaires regarding
patient outcome were sent in September 2005,
with information being collected until January
2006. Overall, 25 definite or probable cases of TB
were reported; 21 cases from 19 different centres
were retained for analysis (two cases could not be
validated by an on-site visit, one patient was
declared twice, and the diagnosis of TB was not
appropriate in one case).
The underlying inflammatory disease, patient
demographical characteristics and concomitant
immunosuppressive treatments are summarised
in Table 1. Most patients had rheumatoid arthritis
and all were receiving infliximab. Seventeen
patients were also treated with corticosteroids at
the time of diagnosis, with a median daily dose of
prednisolone 10 mg (range 4–65 mg). Additional
immunosuppressive factors included chronic hep-
atitis C (n = 1) andneoplasia (n = 4),with the latter
comprising one thyroid carcinoma that was diag-
nosed and treated surgically after starting inflix-
imab, one endometrial carcinoma treated and
cured 7 years before starting TNF-a blocker ther-
apy, one breast carcinoma treated 11 years before
starting TNF-a blocker therapy, and one case of
chronic lymphoid leukaemia diagnosed 1 month
after the initiation of TNF-a blocker therapy. These
patients received TNF-a blockers because they had
very severe forms of rheumatoid arthritis.
Nine (43%) patients reported previous contact
with a patient with TB and ⁄ or primary infection
or microbiologically confirmed TB treated with
anti-TB treatment (Table 2). Fever was the initial
symptom in 16 patients. The mean duration
between first symptoms and the diagnosis of TB
was 38 days (range 3–153 days). In eight (38%)
patients, the lung was the only organ involved,
with five patients having a prolonged cough. Four
(19%) patients only had extra-pulmonary
involvement, comprising lymphadenitis in all
four cases. In eight (38%) patients, the lung and
at least one other system were involved: lymph-
adenitis in three cases; peritonitis in one case;
urinary tract infection in one case; bone (elbow)
involvement in one case; the spleen in one case;
and a combination of lymphadenitis, the spleen
and hepatic involvement in the remaining case.
One patient had no precise clinical localisation.
As reported previously [4], the frequency of extra-
pulmonary and disseminated forms of TB was
particularly high (57%) in these patients who
were treated with TNF-a blockers. Direct smear
microscopy examination of specimens was posi-
tive for acid-fast bacilli in six of 21 patients, and
culture was positive for M. tuberculosis in 19
patients. Of the two patients with negative culture
results, one yielded a bronchoalveolar lavage
fluid that was positive according to a M. tuber-
culosis complex-specific PCR, and the other
patient had a positive Mantoux test (6–20 mm)
with compatible clinical symptoms and a good
response to anti-TB treatment.
Patients received anti-TB therapy for a mean of
8.5 months (range 1–14 months); seven patients
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started with triple therapy (six with isoniazid,
rifampicin and ethambutol; one with isoniazid,
rifampicin and ofloxacin), 13 (61.9%) started with
quadruple therapy (isoniazid, rifampicin, etham-
butol and pyrazinamide), and one died before the
initiation of anti-TB treatment.
TB relapse was observed in one patient in 2004
(microbiologically confirmed lymph node locali-
sation); initial anti-TB treatment had been
received for 6 months and the M. tuberculosis
isolate remained susceptible to all four drugs
taken. This patient recommenced therapy for a
further 9 months and was cured, but did not
resume TNF-a blocker therapy.
Up-to-date information concerning the health
status of patients was obtained via a postal
questionnaire sent c. 4 years after the commence-
ment of anti-TB treatment. At this time, 15
patients were alive and all were cured of TB.
Among the six cases who died, death was
formally attributed to TB in one (4.8%) patient.
Five deaths were not related to TB; these involved
cardiac failure (n = 2), acute respiratory failure
(n = 2) and a cerebrovascular accident (n = 1).
Patients received the following treatment: corti-
costeroids (n = 4); methotrexate (n = 4); lefluno-
mide (n = 4); salazopyrine (n = 1); thalidomide
(n = 1); polyvalent immunoglobulins (n = 1); inf-
liximab (n = 3); etanercept (n = 2; initially n = 3,
but one patient switched to infliximab); and
adalimumab (n = 1).
Six patients recommenced TNF-a blockers at 2
(n = 1), 3 (n = 1), 7.5 (n = 1) and 12 months
(n = 3) after the initiation of anti-TB treatment.
Treatment consisted of infliximab (n = 2), etaner-
cept (n = 3) and adalimumab (n = 1). One patient
in the etanercept group was later switched to
infliximab. None of the six patients who recom-
menced TNF-a antagonist treatment developed a
reactivation of TB or another opportunistic infec-
tion, and their subjective quality of life improved.
The mean follow-up time for these six patients
since commencing anti-TB treatment was
42.7 months (range 18–60 months).
The guidelines of the British Society for Rheu-
matology [8,9] recommend continuation of TNF-a
blockers (with treatment of TB) for patients
who develop active TB while receiving TNF-a
Table 1. Underlying conditions and immunosuppressive therapy in 21 patients treated with tumour necrosis factor (TNF)-
a blockers who developed tuberculosis in France
Rheumatoid
arthritis
(n = 14, 66.7%)
Ankylosing
spondylitis
(n = 2, 9.5%)
Crohn’s disease




arthritis (n = 3, 14.3%) Total (n = 21) %
Male ⁄ Female 6 ⁄ 8 1 ⁄ 1 1 ⁄ 1 1 ⁄ 2 9 ⁄ 12
Median age (range) at the first symptom, years 65 (45–85) 50 (46–54) 34 (28–40) 67 (53–63)
Mean (±SD) duration of disease, years 10.1 ± 5.0 32.2 ± 2.7 12.4 ± 4.1 12.6 ± 6.6
Type of treatment at diagnosis of tuberculosis
I
I + azathioprine 1 0 0 2 3 14.3
I + cyclosporine 0 0 1 0 1 4.8
I + leflunomide 1 0 0 0 1 4.8
I + leflunomide 2 0 0 0 2 9.5
Hydroxychloroquine 1 0 0 0 1 4.8
I + methotrexate 9 2 0 1 12 57.1
I + purinethol 0 0 1 0 1 4.8
Corticosteroidsa 12 1 1 3 17 81
Infliximab treatment
Mean (±SD) infliximab dosage (mg ⁄ kg) 3.3 ± 0.5 3.0 ± 0.0 5.1 ± 0.2 6.5 ± 3.0 3.9 ± 1.7 –
Mean (±SD) number of infliximab perfusions at first symptoms 3.5 ± 1.9 3.0 ± 0.0 3.0 ± 0.0 3.0 ± 1.0 3.3 ± 1.6 –
Mean (±SD) duration of treatment with infliximab (weeks) 13 ± 12.5 12 ± 3.1 26.5 ± 13 9.4 ± 3.6 13.5 ± 11.4 –
Mean (±SD) duration of immunosuppression (years) 8.1 ± 4.5 7.6 ± 12.8 6.6 ± 2.5 7.4 ± 9.2 7.8 ± 6.0 –
I, infliximab.
aCorticosteroids were combined with immunosuppressive therapy.
Table 2. Past medical history of 21 patients with tubercu-








Vaccination (BCG) 5 (24) 7 (33)b 9 (43)
Previous exposure to Mycobacterium
tuberculosis
6 (29) 13 (62) 2 (10)
Past history of tuberculosis primary
infection
7 (33) 12 (57) 2 (10)
Treatment of tuberculosis primary
infection (TPI)
2 (29) 2 (29) 3 (42)
Past history of tuberculosis disease 1 (5) 19 (90) 1 (5)
BCG, bacille Calmette-Gue´rin.
aAll of these patients had received vaccination at least 10 years before diagnosis.
bThese seven patients comprised three immigrants, with the other four patients
being born in France in 1920, 1942 (past history of TPI), 1946 (past history of TPI)
and 1955 (past history of TPI).
Research Notes 185
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 174–189
blockers, provided that the expected benefit to
treatment of the inflammatory disease is signifi-
cant. To our knowledge, this is the first study to
describe the long-term surveillance of patients
who developed TB while being treated with
TNF-a blocker therapy, and who then resumed
TNF-a treatment after being treated successfully
for TB. The data suggest that TB is not a
contraindication to recommencing anti-TNF-a
therapy if this would be beneficial for the under-
lying inflammatory disease.
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ABSTRACT
The decreasing prevalence of anti-Toxoplasma
antibodies in Europe has re-opened the question
of the appropriateness of serological screening
during pregnancy. A study of 3426 pregnant
women, resident in the Legnano area of Italy,
revealed that the IgG seroprevalence according to
ELISA was 21.5%, and that of IgM according to
ELISA and enzyme-linked fluorescent assay was
1.2% and 0.9%, respectively. The incidence of
infection, estimated on the basis of IgG avidity,
was 0.9%. These results confirm a decrease in the
prevalence of IgG, but indicate a high incidence of
infection, thus suggesting that screening for anti-
Toxoplasma antibodies during pregnancy should
be maintained.
Keywords Antibodies, incidence, pregnancy, screen-
ing, seroprevalence, Toxoplasma
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